Trial
NCT05447663
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Siremadlin
Why stopped
Study has been stopped following the strategic decision from the Sponsor. Not based on any safety findings or safety concerns with siremadlin.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-16